Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) Operating Expenses: 2019-2023

Historic Operating Expenses for ADC Therapeutics (ADCT) over the last 5 years, with Sep 2023 value amounting to $50.6 million.

  • ADC Therapeutics' Operating Expenses rose 163.75% to $50.6 million in Q3 2023 from the same period last year, while for Sep 2023 it was $38.9 million, marking a year-over-year increase of 115.38%. This contributed to the annual value of -$333,535 for FY2022, which is 12.82% down from last year.
  • According to the latest figures from Q3 2023, ADC Therapeutics' Operating Expenses is $50.6 million, which was down 14.07% from $58.9 million recorded in Q2 2023.
  • In the past 5 years, ADC Therapeutics' Operating Expenses ranged from a high of $58.9 million in Q2 2023 and a low of -$86.9 million during Q1 2022.
  • For the 3-year period, ADC Therapeutics' Operating Expenses averaged around -$39.1 million, with its median value being -$70.7 million (2021).
  • Its Operating Expenses has fluctuated over the past 5 years, first slumped by 164,457.94% in 2020, then skyrocketed by 167.97% in 2023.
  • Over the past 5 years, ADC Therapeutics' Operating Expenses (Quarterly) stood at -$35,732 in 2019, then crashed by 159,532.19% to -$52.4 million in 2020, then crashed by 35.31% to -$79,791 in 2021, then dropped by 0.93% to -$80,536 in 2022, then skyrocketed by 163.75% to $50.6 million in 2023.
  • Its Operating Expenses was $50.6 million in Q3 2023, compared to $58.9 million in Q2 2023 and -$70.6 million in Q1 2023.